Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Fosbretabulin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 known ✓ | Q9H4B7 | 14/20 | 0.61 |
| ▸ | TUBB4A known ✓ | P04350 | 8/20 | 0.61 |
| ▸ | TUBB known ✓ | P07437 | 8/20 | 0.61 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 8/20 | 0.61 |
| ▸ | TUBA1B known ✓ | P68363 | 8/20 | 0.61 |
| ▸ | TUBA4A known ✓ | P68366 | 8/20 | 0.61 |
| ▸ | TUBB4B known ✓ | P68371 | 8/20 | 0.61 |
| ▸ | TUBB3 known ✓ | Q13509 | 8/20 | 0.61 |
| ▸ | TUBB2A known ✓ | Q13885 | 8/20 | 0.61 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 8/20 | 0.61 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 8/20 | 0.61 |
| ▸ | TUBA1A known ✓ | Q71U36 | 8/20 | 0.61 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 8/20 | 0.61 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 8/20 | 0.61 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 8/20 | 0.61 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.61 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.61 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.61 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fosbretabulin SCHEMBL29374788 | 1.00 | TUBB1 (0.61) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL29417596 | 1.00 | TUBB1 (0.61) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL3179235 | 0.99 | TUBB1 (0.60) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL9707816 | 0.99 | TUBB1 (0.60) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL9708418 | 0.99 | TUBB1 (0.60) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL3542758 | 0.99 | TUBB1 (0.60) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL14175312 | 0.97 | TUBB1 (0.61) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL14114359 | 0.92 | TUBB1 (0.64) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13940886 | 0.91 | TUBB1 (0.61) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13813245 | 0.90 | TUBB1 (0.51) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2001 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115305-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| US-20260077056-A1 | LINKER-PAYLOAD COMPOUND, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-03-19 | — | — | US | claimed |
| EP-4694935-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ANTI-PD-1 ANTIBODY, AND USE THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. (CN) | 2026-02-18 | — | — | EP | claimed |
| EP-4688871-A1 | SITE-SPEICFIC ORTHOGONAL BIOCONJUGATE MODALITY AND APPLICATION THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. (CN) | 2026-02-11 | — | — | EP | claimed |
| US-20250387505-A1 | ANTI-FGFR3 ANTIBODY CONJUGATE AND MEDICAL USE THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2025-12-25 | — | — | US | claimed |
| EP-4601702-A1 | LINKER-PAYLOAD COMPOUND, CONJUGATES AND APPLICATIONS THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. (CN) | 2025-08-20 | — | — | EP | claimed |
| EP-4313156-B1 | DISULFIDE-BASED PRODRUG COMPOUNDS | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2025-08-06 | — | — | EP | claimed |
| WO-2022218331-A9 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2025-06-19 | — | — | WO | claimed |
| EP-4554626-A2 | ANTI-TROP2 ANTIBODY AND CONJUGATE THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. (CN) | 2025-05-21 | — | — | EP | claimed |
| EP-4554956-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. (CN) | 2025-05-21 | — | — | EP | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2002006279-A9 | EFFICIENT METHOD OF SYNTHESIZING COMBRETASTATIN A-4 PRODRUGS | OXIGENE INC (US) | 2003-04-03 | — | — | WO | claimed |
| EP-1294403-A2 | TRIPEPTIDE PRODRUG COMPOUNDS | CORIXA CORPORATION (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2002100353-A2 | CD10-ACTIVATED PRODRUG COMPOUNDS | MEDAREX, INC. (US) | 2002-12-19 | — | — | WO | claimed |
| US-20020142955-A1 | Enzyme-cleavable prodrug compounds | E. R. SQUIBB & SONS, L.L.C. | 2002-10-03 | — | — | US | claimed |
| US-20020119951-A1 | Efficient method of synthesizing combretastatin A-4 prodrugs | MATEON THERAPEUTICS, INC. | 2002-08-29 | — | — | US | claimed |
| WO-2002006279-A2 | — | — | 2002-01-24 | — | — | WO | claimed |
| WO-2002006279-A1 | EFFICIENT METHOD OF SYNTHESIZING COMBRETASTATIN A-4 PRODRUGS | OXIGENE INC (US) | 2002-01-24 | — | — | WO | claimed |
| WO-2002000263-A2 | TRIPEPTIDE PRODRUG COMPOUNDS | MEDAREX, INC. (US) | 2002-01-03 | — | — | WO | claimed |
| WO-1992016486-A1 | SUBSTITUTED DIPHENYLETHYLENES AND ANALOGUES OR DERIVATIVES THEREOF | ASTON MOLECULES LIMITED (GB) | 1992-10-01 | — | — | WO | claimed |